Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (Q36087976)

12 August 2017

Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Rajesh Krishna

1

1 reference

12 August 2017

Daria Stypinski

2

1 reference

12 August 2017

Melissa Ali

3

1 reference

12 August 2017

Amit Garg

4

1 reference

12 August 2017

Josee Cote

5

1 reference

12 August 2017

Andrea Maes

6

1 reference

12 August 2017

Bruce Degroot

7

1 reference

12 August 2017

Yang Liu

8

1 reference

12 August 2017

Susie Li

9

1 reference

12 August 2017

Sandra M Connolly

10

1 reference

12 August 2017

John A Wagner

11

1 reference

12 August 2017

S Aubrey Stoch

12

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

British Journal of Clinical Pharmacology

12 August 2017

1 reference

12 August 2017

74

1 reference

12 August 2017

1

1 reference

12 August 2017

116-124

1 reference

Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Human P450 metabolism of warfarin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Plasma cholesteryl ester transfer protein

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

2 October 2017

Oral anticoagulant drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Safety of anacetrapib in patients with or at high risk for coronary heart disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Calibration of reference thromboplastins and standardisation of the prothrombin time ratio.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3394135

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

11 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2012.04171.X

Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects

21 January 2018

1 reference

12 December 2020

Drug interactions with warfarin

1 reference

12 December 2020

Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

1 reference

12 December 2020

Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects

1 reference

12 December 2020

10.1111/J.1365-2125.2012.04171.X

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22243494

1 reference